Pharmesis International Ltd.

BFK

SG1BH6000003

Pharmaceuticals

Market Closed - Singapore S.E. Other stock markets 05:59:02 08/05/2024 BST			5-day change	1st Jan Change
0.105 ^SGD	-5.41%		-5.41%	+7.14%

04-30	Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	CI
04-30	Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	CI

Pharmesis International Ltd. Appoints Cheok Hui Yee as Company Secretary

May 30, 2022 at 10:22 am

The Board of Directors of Pharmesis International Ltd. announced the appointment of Ms. Cheok Hui Yee as Company Secretary of the Company with effect from 30 May 2022. Following the above appointment, the Company Secretaries of the Company are Ms. Chan Lai Yin and Ms. Cheok Hui Yee.

Latest news about Pharmesis International Ltd.

Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	04-30	CI
Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	04-30	CI
Pharmesis International Ltd. Announces Retirement of Lin Yimin as Member of Audit Committee	04-29	CI
Pharmesis’ Attributable Loss for 2023 Widens	04-15	MT
Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director	04-15	CI
Pharmesis Launches New Product Line	03-26	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months and Full Year Ended 31 December 2023	02-28	CI
Pharmesis International Ltd. Announces Changes to the Composition of the Board and Board Committees	29/09/23	CI
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23	CI
Pharmesis International Flags Losses for H1	09/08/23	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	08/08/23	CI
Pharmesis International Ltd. Announces Management Resignations	31/07/23	CI
Pharmesis International Ltd. Appoints Lin Yimin as Non-Independent Non-Executive Director and A Member of Audit Committee	31/07/23	CI
Pharmesis International Ltd. Announces Temporary Work Stoppages at its Manufacturing Facilities Located in Gulin County, Luzhou City, Sichuan Province	27/07/23	CI
Pharmesis International Issues 4.6 Million Shares to Two Subscribers	06/04/23	MT
Pharmesis International Gets Regulatory Nod to List 4.6 Million Shares	29/03/23	MT
Pharmesis International to Issue 4.6 Million Shares to Two Subscribers	21/03/23	MT
Pharmesis International Expects Loss in H2, FY22	28/02/23	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Pharmesis International's Attributable Loss Widens in H1	15/08/22	MT
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	12/08/22	CI
Pharmesis International to Post Losses in H1 Amid Lower Sales	08/08/22	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2022	05/08/22	CI
Pharmesis International Ltd. Appoints Cheok Hui Yee as Company Secretary	30/05/22	CI

Chart Pharmesis International Ltd.

Duration

Period

More charts

Company Profile

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMESIS INTERNATIONAL LTD.	+7.14%	2.14M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B